Why Charles River Laboratories International, Inc. (CRL) stock moved
Charles River Laboratories International, Inc. (CRL) shares fell 2.1% to $219.70 as of July 21, 2026, a modest decline from the prior close of $224.35. BestStocks flagged the session as a major change for CRL. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for CRL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
CRL fell 2.1% to $219.70
CRL fell 2.1% in its latest session, moving from $224.35 to $219.70.
What it means for Charles River Laboratories International, Inc. investors
For Charles River Laboratories International, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Charles River Laboratories International, Inc. (CRL) moved +4.30% from $223.96 to $233.60 on 2026-07-09, reaching a new 30-day high; CRL moved +0.32% from $230.69 to $231.43 on 2026-07-06. Weighing against that: Negative session, down 2.1%; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $230.78, implying +5.0% upside from $219.70. Over the past 90 days analysts logged 2 upgrades and 0 downgrades. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 15 days out, the next report is the most likely near-term test of the move.
CRL price reaction
CRL last traded at $219.70, down $4.65 (-2.07%) from the previous close of $224.35. The session traded on 1.1× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $181.56 and $233.60, and it currently sits about 73% of the way up that band.
Bullish and bearish analyst opinions on Charles River Laboratories International, Inc. (CRL)
The consensus analyst price target on Charles River Laboratories International, Inc. (CRL) is $230.78, 5.0% above the recent $219.70. Over the past 90 days analysts logged 2 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CRL line up.
The bullish case
- Wall Street's consensus price target of $230.78 implies +5.0% upside from $219.70.
- The Street's most bullish target is $260.00 (+18.3%).
- 2 analyst upgrades in the past 90 days, most recently Morgan Stanley to Overweight (2026-06-17).
- Charles River Laboratories International, Inc. (CRL) moved +4.30% from $223.96 to $233.60 on 2026-07-09, reaching a new 30-day high.
- CRL moved +0.32% from $230.69 to $231.43 on 2026-07-06.
The bearish case
- The most bearish analyst target is $213.00 (-3.0%).
- Negative session, down 2.1%.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CRL
Frequently asked questions about CRL
Why did Charles River Laboratories International, Inc. (CRL) stock move?
CRL fell 2.1% to $219.70. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did CRL stock fall?
CRL lost 2.07% ($4.65) versus the prior close of $224.35, last trading at $219.70 on 1.1× average volume.
When is Charles River Laboratories International, Inc.'s next earnings date?
CRL's next earnings report is estimated for 2026-08-05 — about 15 days away.
What is the analyst price target for CRL?
The consensus analyst price target for CRL is $230.78, about 5.0% above the current $219.70. Over the past 90 days, analysts recorded 2 upgrades, 4 maintains, and 0 downgrades.
How BestStocks tracks CRL
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared CRL-specific materiality thresholds, triggering an evidence check. It draws on 6 tracked change events for CRL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.